Shares of Pfizer, Eli Lilly, and Novo Nordisk fell on Monday, May 18, 2026.
The decline follows reports of an expected expansion of the TrumpRx discounted drug program. This policy aims to lower prescription medication costs for Americans.
The announcement creates pricing pressure and uncertainty for pharmaceutical companies. Pfizer’s stock declined in line with the broader sector.
The development overshadowed analyst discussions regarding stock valuations and clinical pipeline updates.